$360,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care. Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Final CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)."
You can find more data on corporate lobbying on Quiver Quantitative.
AKBA Insider Trading Activity
AKBA insiders have traded $AKBA stock on the open market 17 times in the past 6 months. Of those trades, 1 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $AKBA stock by insiders over the last 6 months:
- JOHN P. BUTLER (CEO and President) has made 1 purchase buying 69,270 shares for an estimated $86,587 and 4 sales selling 341,305 shares for an estimated $474,413.
- NICHOLAS GRUND (Chief Commercial Officer) has made 0 purchases and 2 sales selling 84,829 shares for an estimated $117,912.
- ERIK OSTROWSKI (SVP, CFO, CBO & Treasurer) has made 0 purchases and 2 sales selling 90,970 shares for an estimated $110,762.
- CAROLYN M. RUCCI (SVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 69,772 shares for an estimated $96,983.
- STEVEN KEITH BURKE (SVP, Chief Medical Officer) has made 0 purchases and 3 sales selling 67,658 shares for an estimated $94,044.
- RICHARD C MALABRE (SVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 49,524 shares for an estimated $68,838.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AKBA Hedge Fund Activity
We have seen 60 institutional investors add shares of AKBA stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 3,275,470 shares (-70.2%) from their portfolio in Q1 2026, for an estimated $4,552,903
- STATE STREET CORP removed 2,073,555 shares (-15.1%) from their portfolio in Q1 2026, for an estimated $2,882,241
- RENAISSANCE TECHNOLOGIES LLC removed 1,760,005 shares (-49.0%) from their portfolio in Q1 2026, for an estimated $2,446,406
- FEDERATED HERMES, INC. removed 1,291,172 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,794,729
- TWO SIGMA INVESTMENTS, LP added 1,207,182 shares (+1332.2%) to their portfolio in Q1 2026, for an estimated $1,677,982
- AQR CAPITAL MANAGEMENT LLC added 1,145,941 shares (+177.2%) to their portfolio in Q1 2026, for an estimated $1,592,857
- GOLDMAN SACHS GROUP INC removed 1,103,610 shares (-23.4%) from their portfolio in Q1 2026, for an estimated $1,534,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AKBA Analyst Ratings
Wall Street analysts have issued reports on $AKBA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
To track analyst ratings and price targets for AKBA, check out Quiver Quantitative's $AKBA forecast page.
AKBA Price Targets
Multiple analysts have issued price targets for $AKBA recently. We have seen 3 analysts offer price targets for $AKBA in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $6.0 on 07/01/2026
- Julian Harrison from BTIG set a target price of $4.0 on 04/07/2026
- Allison Bratzel from Piper Sandler set a target price of $4.0 on 02/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
